Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients

Xinhuan WEI; Jing ZHANG; Zhili ZHANG; Yan LIU; Lijuan FAN; Jian SONG; Yuening ZHANG

doi:10.3969/j.issn.1001-5256.2023.07.010

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1570-1577

PDF( 2041 KB)

Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients

DOI: 10.3969/j.issn.1001-5256.2023.07.010

a.
Third Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
b.
Department of Medical Service, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Incubation Program for Young and Middle-aged Talents in Beijing YouAn Hospital Affiliated to Capital Medical University (YNKTJL2021001)

More Information

Corresponding author: ZHANG Yuening, zyn1625@ccmu.edu.cn (ORCID: 0000-0003-2205-3413)
Received Date: 2022-11-30
Accepted Date: 2023-01-09
Published Date: 2023-07-20

Abstract

Abstract

Objective Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare cause of portal hypertension, and this study aims to analyze the clinical features of patients with INCPH, and to assist in diagnosis and differential diagnosis. Methods A total of 74 patients who were hospitalized in Beijing YouAn Hospital from January 2019 to July 2022 and were diagnosed with INCPH were enrolled, and 332 patients with liver cirrhosis who were hospitalized during the same period of time were enrolled as control group. Demographic data, laboratory markers, gastroscopy, liver elasticity, pathological examination, and complications were recorded and compared between the two groups. The receiver operating characteristic (ROC) curve was used to investigate the ability of liver stiffness measurement (LSM), aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4) in the differential diagnosis of INCPH, and the DeLong test was used to compare the area under the ROC curve (AUC). The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. Results Among the patients with INCPH, 46.55% had no obvious symptoms at disease onset and 43.24% were misdiagnosed with liver cirrhosis. Compared with the patients with liver cirrhosis, the patients with INCPH had a significantly higher proportion of patients with gastrointestinal bleeding (62.16% vs 41.27%, χ²=10.67, P < 0.01) and a significantly lower proportion of patients with moderate-to-severe ascites (16.21% vs 29.82%, χ²=34.98, P < 0.01), and there were few patients with hepatic encephalopathy. As for pathology, 89.19% (66/74) of the INCPH patients manifested as typical occlusive portal vein disease. The statistical analysis showed that compared with the patients with liver cirrhosis, the patients with INCPH had significantly better liver function parameters, MELD score, and Child-Pugh score and significantly lower LSM [9.05(7.18-12.33) vs 25.32(16.21-47.23), Z=-8.41, P < 0.01], APRI score [0.70(0.41-1.28) vs 1.35(0.80-2.39), Z=-6.21, P < 0.01], and FIB-4 index [2.99(1.62-4.81) vs 6.68(4.06-10.42), Z=-8.39, P < 0.01]. LSM, FIB-4, and APRI had a good ability in differentiating INCPH from liver cirrhosis, and in particular, LSM had an AUC of up to 0.92 (95% confidence interval: 0.87-0.96), with a sensitivity of 92.68% and a specificity of 81.60%. Conclusion INCPH patients tend to have an insidious onset, a relatively high incidence rate of portal hypertension-related complications, and relatively good liver function, especially the patients with LSM < 14.5 kPa. The possibility of INCPH should be considered for such patients in clinical practice.
- Hypertension, Portal,
- Idiopathic non-Cirrhotic Portal Hypertension,
- Liver Cirrhosis,
- Complications

FullText(HTML)

References(24)

References

[1]	Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Chinese expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(4): 444-455. DOI: 10.3760/cma.j.cn115610-20220223-00104. 中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝细胞癌临床诊断与治疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(4): 444-455. DOI: 10.3760/cma.j.cn115610-20220223-00104.
[2]	HUANG D, CAO JG, YE HY, et al. Occurrence and progression of hemodynamic dysfunction in cirrhotic portal hypertension[J]. Chin J Dig Surg, 2021, 20(10): 1117-1122. DOI: 10.3760/cma.j.cn115610-20210813-00394. 黄登, 曹君贵, 叶航羊, 等. 肝硬化门静脉高压血流动力学紊乱发生及发展机制[J]. 中华消化外科杂志, 2021, 20(10): 1117-1122. DOI: 10.3760/cma.j.cn115610-20210813-00394.
[3]	XU JH, YU YY, XU XY. Current status of the clinical management of non-cirrhotic portal hypertension[J]. J Clin Hepatol, 2022, 38(7): 1457-1459. DOI: 10.3969/j.issn.1001-5256.2022.07.001. 徐京杭, 于岩岩, 徐小元. 非肝硬化性门静脉高压症的临床管理现状[J]. 临床肝胆病杂志, 2022, 38(7): 1457-1459. DOI: 10.3969/j.issn.1001-5256.2022.07.001.
[4]	European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
[5]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
[6]	WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38(2): 518-526. DOI: 10.1053/jhep.2003.50346.
[7]	TESHALE E, LU M, RUPP LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)[J]. J Viral Hepat, 2014, 21(12): 917-920. DOI: 10.1111/jvh.12279.
[8]	SATO Y, REN XS, HARADA K, et al. Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies[J]. Clin Exp Immunol, 2012, 167(3): 532-542. DOI: 10.1111/j.1365-2249.2011.04530.x.
[9]	SCHOUTEN JN, GARCIA-PAGAN JC, VALLA DC, et al. Idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2011, 54(3): 1071-1081. DOI: 10.1002/hep.24422.
[10]	GOEL A, ELIAS JE, EAPEN CE, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)-newer insights into pathogenesis and emerging newer treatment options[J]. J Clin Exp Hepatol, 2014, 4(3): 247-256. DOI: 10.1016/j.jceh.2014.07.005.
[11]	de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[12]	OKUDAIRA M, OHBU M, OKUDA K. Idiopathic portal hypertension and its pathology[J]. Semin Liver Dis, 2002, 22(1): 59-72. DOI: 10.1055/s-2002-23207.
[13]	PULVIRENTI F, PENTASSUGLIO I, MILITO C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies[J]. J Immunol Res, 2014, 2014: 672458. DOI: 10.1155/2014/672458.
[14]	GUIDO M, SARCOGNATO S, SACCHI D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31. DOI: 10.1007/s00428-018-2355-8.
[15]	EAPEN CE, NIGHTINGALE P, HUBSCHER SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors[J]. Dig Dis Sci, 2011, 56(1): 227-235. DOI: 10.1007/s10620-010-1278-2.
[16]	CAZALS-HATEM D, HILLAIRE S, RUDLER M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis[J]. J Hepatol, 2011, 54(3): 455-461. DOI: 10.1016/j.jhep.2010.07.038.
[17]	VERNIER-MASSOUILLE G, COSNES J, LEMANN M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine[J]. Gut, 2007, 56(10): 1404-1409. DOI: 10.1136/gut.2006.114363.
[18]	SANTRA A, DAS GUPTA J, DE BK, et al. Hepatic manifestations in chronic arsenic toxicity[J]. Indian J Gastroenterol, 1999, 18(4): 152-155.
[19]	GUIDO M, ALVES V, BALABAUD C, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition[J]. Histopathology, 2019, 74(2): 219-226. DOI: 10.1111/his.13738.
[20]	MADHU K, AVINASH B, RAMAKRISHNA B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital[J]. Indian J Gastroenterol, 2009, 28(3): 83-87. DOI: 10.1007/s12664-009-0030-3.
[21]	NAYAK NC, JAIN D, SAIGAL S, et al. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease[J]. J Clin Pathol, 2011, 64(7): 592-598. DOI: 10.1136/jcp.2010.087395.
[22]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[23]	SEIJO S, REVERTER E, MIQUEL R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension[J]. Dig Liver Dis, 2012, 44(10): 855-860. DOI: 10.1016/j.dld.2012.05.005.
[24]	KHANNA R, SARIN SK. Non-cirrhotic portal hypertension - diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013.

Relative Articles

[1]	Fang WANG, Jianhua LU, Yonggang LIU, Xinyu ZHANG, Huimin YAN. Expression and significance of immune cells in patients with hepatitis B virus-related acute-on-chronic pre-liver failure[J]. Journal of Clinical Hepatology, 2023, 39(1): 77-82. doi: 10.3969/j.issn.1001-5256.2023.01.012
[2]	Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
[3]	Yifei GUO, Jiming ZHANG. Influencing factors for the functional cure of chronic hepatitis B and related mechanism[J]. Journal of Clinical Hepatology, 2022, 38(8): 1721-1725. doi: 10.3969/j.issn.1001-5256.2022.08.004
[4]	Zixiang GAO, Zhongliang SHEN, Jing LIU, Youhua XIE. Research advances in cytokines in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(8): 1710-1715. doi: 10.3969/j.issn.1001-5256.2022.08.002
[5]	Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031
[6]	Xiaofei YANG, Linxu WANG, Changxing HUANG, Jie DONG, Haifeng HU, Zhanhu BI, Jianqi LIAN, Ye ZHANG. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8⁺ T cells of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2021, 37(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2021.05.017
[7]	Limin WANG, Shuhong LIU, Shishu ZHU, Yi DONG, Zhiqiang XU, Fuchuan WANG, Jianguo YAN, Pu WANG, Aiqin LI, Lili CAO, Pan ZHAO, Min ZHANG. Association of the expression of HBsAg and HBcAg in liver tissue with antiviral response in children with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(1): 46-50. doi: 10.3969/j.issn.1001-5256.2021.01.010
[8]	Zhen PENG, Huiming JIN, Huibin NING, Kuan LI, Jia SHANG. Value of lymphocyte subset testing in predicting HBsAg decline in chronic hepatitis B patients receiving antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(9): 2071-2074. doi: 10.3969/j.issn.1001-5256.2021.09.014
[9]	Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009
[11]	Peng JianPing, Sun KeWei, Yin SiHan, Wu YuNan. Effects of hepatitis B virus on the expression of Toll-like receptor 9,interferon regulatory factor-7,and interferon-α in plasmacytoid dendritic cells in the umbilical cord blood of healthy parturients[J]. Journal of Clinical Hepatology, 2016, 32(5): 894-898. doi: 10.3969/j.issn.1001-5256.2016.05.016
[12]	Yin SiHan, Liu Peng, Zhang Tao, Sun KeWei. Analysis of TCM deficiency and excess attributes in patients with HBV- related acute- on- chronic liver failure based on phenotype of dendritic cells and function of T lymphocytes[J]. Journal of Clinical Hepatology, 2016, 32(4): 663-668. doi: 10.3969/j.issn.1001-5256.2016.04.010
[13]	Jia Lin, Li Juan, Zhu YueKe, Zhao Juan, Liu HaiXia, Duan ZhongHui, Ren MeiXin, Meng QingHua. Count of peripheral blood dendritic cells and its clinical significance in patients with acute-on-chronic hepatitis B liver failure[J]. Journal of Clinical Hepatology, 2015, 31(5): 711-715. doi: 10.3969/j.issn.1001-5256.2015.05.019
[14]	Peng JianPing, Sun KeWei, Wu YuNan, Zhang QianQian. Programmed cell death 1 expression on HBV-specific CTLs induced by dendritic cells in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(12): 926-929.
[15]	Jiang Na, Pan Lei, Li Yuan, Zhang SuMei, Zhang Ying, Ma Li, Zhou Yun, Guo YaLing, Jia ZhanSheng. Antiviral treatment-induced phenotype changes in dendritic cells of peripheral blood from chronic HCV patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 446-449+455.
[16]	Shi QingFeng, Zhang YingXin, Song JiKui, Yuan JianGuo, Li QingFang, Zhao HongKui, Ceng WeiQun, Chen Min. Effect of prostaglandin E1 on the dendritic cells maturation and the activity of CD4+/CD8+ T cells in chronic severe hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(3): 212-215.
[17]	Zhou Yun, Li Duan, Chen Lin, Zhao FuTao, Ma Li, Wang Hong, Pan Lei, Jia ZhanSheng. The construction of HCV multi-CTL epitopes dendritic cell vaccine and its effect of stimulating T cell response in vitro[J]. Journal of Clinical Hepatology, 2011, 27(1): 40-44.
[18]	Zou XiaoJing, Jiang XueQiang, Tian DeYing. Role of DC-SIGN on the maturation and activation of dendritic cells in chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2011, 27(2): 145-147+153.
[19]	Feng XiaoXia, Wang Lei, Xing LianJun, Liang HaiLin, Nie YuanXia. The function of dendritic cell in chronic hepatitis B patients with deficiency of kidney based on traditional chinese medicine syndrome differentiation intervention[J]. Journal of Clinical Hepatology, 2010, 26(6): 638-640.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (416) PDF downloads(62)

Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients

DOI: 10.3969/j.issn.1001-5256.2023.07.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients

DOI: 10.3969/j.issn.1001-5256.2023.07.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content